-
1.发明授权Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same 有权具有增加的生物利用度的芬维A胺的药物组合物及其使用方法公开(公告)号：US07169819B2
公开(公告)日：2007-01-30
申请号：US10010914
申请日：2001-12-05
CPC分类号： A61K31/16 , A61K9/107 , A61K9/1075 , A61K31/164 , A61K31/167 , A61K47/10 , A61K47/44 , Y10S514/937 , Y10S514/938 , Y10S514/975
摘要： A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.
摘要翻译： 一种用于胃肠外递送的药物组合物，其包含视网膜如芬维A胺与能够分散或溶解视黄酸盐的溶剂的组合。 溶剂包括醇，如乙醇，与烷氧基化蓖麻油（如ELEM）组合，或在分散在水相中的脂质组成的乳液中包含视黄酸盐，如芬维A胺，稳定剂 非离子表面活性剂，任选的溶剂和任选的等渗剂的量。 此外，描述了用于治疗过度增殖性疾病如癌症的方法。
-
公开(公告)号：US07476692B2
公开(公告)日：2009-01-13
申请号：US10782459
申请日：2004-02-19
CPC分类号： A61K31/133 , A61K9/0019 , A61K9/08 , A61K9/107 , A61K9/19 , A61K31/19 , A61K31/685 , A61K31/739 , A61K47/10 , A61K47/12 , A61K47/26
摘要： The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.
摘要翻译： 本发明提供基本上由以下组成的稳定的水溶液：（a）鞘脂; （b）乳酸; 和（c）任选的稳定剂; 其中所述溶液的乳酸与鞘脂的摩尔比为1:1至10:1。 本发明还提供一种乳液制剂，其主要由以下物质组成：（a）乳酸; （b）鞘脂，其中所述神经鞘脂以约0.1至约30mg / ml的乳剂的量存在; （b）任选的等渗剂; 和（c）以约0.2至约200mg / ml的乳液的量存在的磷脂。 还提供了制备和使用组合物的方法。
-
公开(公告)号：US06838090B2
公开(公告)日：2005-01-04
申请号：US10455295
申请日：2003-06-05
IPC分类号： A61K9/107 , A61K9/127 , A61K31/33 , A61K31/4192 , A61K31/4196 , A61K47/10 , A61K47/18 , A61K47/20
CPC分类号： A61K31/4196 , A61K9/0019 , A61K9/1075 , A61K9/127 , A61K9/1278 , A61K31/33 , A61K31/4192 , A61K47/10 , A61K47/18 , A61K47/20
摘要： The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.
摘要翻译： 本发明提供了包含水不溶性药物，水不溶性药物的水混溶性有机溶剂，表面活性剂和水的药物递送系统及其制备方法。 本发明还提供了包含药学上可接受的载体和这种药物递送系统的药物组合物。 此外，本发明提供了通过向宿主施用本发明的药物递送系统来向药物递送药物的方法。
-
公开(公告)号：US06682758B1
公开(公告)日：2004-01-27
申请号：US09868858
申请日：2001-06-21
IPC分类号： A61K9127
CPC分类号： A61K31/4196 , A61K9/0019 , A61K9/1075 , A61K9/127 , A61K9/1278 , A61K31/33 , A61K31/4192 , A61K47/10 , A61K47/18 , A61K47/20
摘要： The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.
摘要翻译： 本发明提供了包含水不溶性药物，水不溶性药物的水混溶性有机溶剂，表面活性剂和水的药物递送系统及其制备方法。 本发明还提供了包含药学上可接受的载体和这种药物递送系统的药物组合物。 此外，本发明提供了通过向宿主施用本发明的药物递送系统来向药物递送药物的方法。
-
公开(公告)号：US20050282742A1
公开(公告)日：2005-12-22
申请号：US11184622
申请日：2005-07-19
申请人： Louis Plamondon , Louis Grenier , Julian Adams , Shanker Gupta
发明人： Louis Plamondon , Louis Grenier , Julian Adams , Shanker Gupta
IPC分类号： A61K9/19 , A61K31/69 , A61K38/00 , A61K38/14 , A61P29/00 , A61P31/18 , A61P35/00 , A61P37/02 , A61P43/00 , C07F5/02 , C07F5/04 , C07F5/05 , C07H9/00 , C07K5/06 , C07K5/062 , C07K5/065 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/097 , C07K5/117 , C07K7/02 , C07K9/00
摘要： The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.
摘要翻译： 本发明涉及药物化合物的制剂。 更具体地，本发明提供由硼酸化合物制备的稳定的药学上可接受的组合物和制备组合物的方法。 本发明还提供新的硼酸酯化合物。 本发明还提供了可用于本发明方法的硼酸酐化合物。
-
公开(公告)号：US20050187186A1
公开(公告)日：2005-08-25
申请号：US10782459
申请日：2004-02-19
申请人： Barry Maurer , Shanker Gupta , C. Reynolds , B. Vishnuvajjala
发明人： Barry Maurer , Shanker Gupta , C. Reynolds , B. Vishnuvajjala
IPC分类号： A61K20060101 , A61K9/00 , A61K9/08 , A61K9/107 , A61K9/19 , A61K31/133 , A61K31/19 , A61K31/685 , A61K31/739 , A61K47/10 , A61K47/12 , A61K47/26 , A61P35/00
CPC分类号： A61K31/133 , A61K9/0019 , A61K9/08 , A61K9/107 , A61K9/19 , A61K31/19 , A61K31/685 , A61K31/739 , A61K47/10 , A61K47/12 , A61K47/26
摘要： The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.
摘要翻译： 本发明提供基本上由以下组成的稳定的水溶液：（a）鞘脂; （b）乳酸; 和（c）任选的稳定剂; 其中所述溶液的乳酸与鞘脂的摩尔比为1:1至10:1。 本发明还提供一种乳液制剂，其主要由以下物质组成：（a）乳酸; （b）鞘脂，其中所述神经鞘脂以约0.1至约30mg / ml的乳剂的量存在; （b）任选的等渗剂; 和（c）以约0.2至约200mg / ml的乳液的量存在的磷脂。 还提供了制备和使用组合物的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.022 秒)
